Endometriosis is exactly the kind of condition that sends women looking beyond conventional medicine: painful, chronic, underdiagnosed for years on average, and offering treatment options — hormonal suppression, surgery, pain management — that many women find incomplete. Into that gap has flowed interest in BPC-157. This article takes the question seriously enough to answer it honestly, in both directions: the theoretical case for interest, and the theoretical concerns that the enthusiastic coverage never mentions.
Why BPC-157 Comes Up for Endometriosis at All
Endometriosis involves tissue resembling the uterine lining growing outside the uterus, driving chronic inflammation, pain, adhesions, and often fertility problems. BPC-157’s animal-research profile includes anti-inflammatory effects, tissue repair, and protective effects on the gut — and since endometriosis frequently involves the bowel and pelvic inflammation, the surface-level match is easy to see. Women also arrive here via adjacent pelvic conditions where BPC-157 discussion already exists, like interstitial cystitis.
What the Research Actually Consists Of
Here is the plain accounting: there are no human clinical trials of BPC-157 for endometriosis. There are, to date, no meaningful animal studies of BPC-157 in endometriosis models either. What exists is inference — general anti-inflammatory and healing findings from unrelated animal research, extrapolated to a condition it was never tested in. That is two extrapolation steps past evidence, and any vendor or clinic implying otherwise is ahead of the science. Our broader review of the space, peptides and endometriosis research, covers what little the whole peptide category offers here.
The Concern Nobody Mentions: Angiogenesis
Now the part the enthusiastic coverage skips. One of BPC-157’s best-documented properties in animal research is promoting angiogenesis — new blood vessel formation. That is central to how it accelerates wound healing. But endometriosis lesions also depend on angiogenesis to establish and sustain themselves; anti-angiogenic approaches have actually been explored as endometriosis therapies. In other words, the same property that makes BPC-157 interesting for tendon repair is, in theory, a property you might not want to hand to endometrial lesions. Is there evidence BPC-157 worsens endometriosis? No — but there is no evidence in either direction, and the mechanistic arrow points in a direction that warrants genuine caution, not just the usual disclaimer.
What Actually Has Evidence for Endometriosis
Because this deserves saying in an article women will find while hurting: excision surgery by an experienced endometriosis specialist, hormonal suppression strategies, and multidisciplinary pain management are the approaches with real evidence. Pelvic floor physical therapy helps many women with the muscular component. If your current care feels dismissive — a common experience — the evidence-based upgrade is a true endometriosis specialist, not a research compound. Peptides with fertility-adjacent relevance are a separate, equally honest conversation: see peptides, IVF, and fertility.
If You're Still Considering It
Some women, fully informed, will still experiment — that is their call to make. The minimum standard: a provider who knows your full picture (especially if fertility preservation matters to you), verified third-party-tested sourcing, one variable at a time, and honest symptom tracking against your baseline. And given the angiogenesis question, “my pain is worsening” is a stop signal, not a push-through signal. Sourcing frameworks live in our compounded vs research vs prescribed guide.